Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 730, Issue -, Pages 26-30Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2014.02.020
Keywords
Melatonin; Natalizumab; Oxidative stress; Relapsing remitting multiple sclerosis; Tysabri (R)
Categories
Ask authors/readers for more resources
Natalizumab is currently the most successful clinical treatment for multiple sclerosis. The use of this drug is associated with the reduction in the number of relapses and a slowing in disease progression, as well as an improvement in signs and symptoms displayed by the patients. To evaluate the effect of natalizumab on melatonin and its relationship with peripheral oxidative damage, we studied the serum melatonin levels in 18 patients with relapsing-remitting multiple sclerosis. Natalizumab caused significant increases in serum melatonin concentrations. This change was associated with a rise in increase of antioxidants and a reduction in oxidative stress biomarkers. In conclusion, these data may explain, at least in part, sonic of the beneficial effects exhibited by disease antibody such as its antioxidant capacity. (C) 2014 Elsevier B.V. All rights reserved
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available